Properties of sustained-release single-dose formulations for vulvovaginal candidiasis

  title={Properties of sustained-release single-dose formulations for vulvovaginal candidiasis},
  author={Milan R. Henzl},
  journal={American Journal of Drug Delivery},
  • M. Henzl
  • Published 1 December 2005
  • Medicine
  • American Journal of Drug Delivery
Vaginally applied imidazoles are the first-line treatment of vulvovaginal candidiasis (VVC). The need to develop a less messy and more patient acceptable treatment regimen led to the development of a treatment schedule from the original 3 weeks to 7 days and, then, to 3 days. Finally, it was attempted to design a single-dose treatment regimen. Currently in the US, three single-dose vaginal preparations are available: 2% butoconazole sustained release (SR) [100mg butoconazole; Gynazole-1®], 6.5… Expand
Treatment of recurrent vulvo-vaginal candidiasis with sustained-released butoconazole pessary.
A sustained-release (SR) bioadhesive vaginal cream (2% butoconazole nitrate) has incorporated VagiSite technology, a topical drug delivery system that allows SR of the drug to be incorporated in the treatment of two cases of RVVC. Expand
Local Treatment of Vulvovaginal Candidosis
In summary, azoles and short-term regimens are usually recommended for the local treatment of vulvovaginal candidosis, with nystatin and boric acid considered as second-line alternatives. Expand
Evaluation of Mucoadhesive Gels with Propolis (EPP-AF) in Preclinical Treatment of Candidiasis Vulvovaginal Infection
Results of in vivo efficacy demonstrated that propolis based gels present antifungal action similar to clotrimazole cream, suggesting that future clinical studies should be performed. Expand
Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology.
Sertaconazole is a well established antifungal agent, which is now available in a variety of formulations, and remains a useful treatment option particularly in patients with fungal infections resistant to other azoles. Expand
Structural characterization and cytotoxic activity of tioconazole coordination compounds with cobalt(II), copper(II), zinc(II) and cadmium(II)
Abstract Coordination compounds of CoII, CuII, ZnII and CdII with tioconazole (tcnz) have been synthesized and fully characterized by different techniques such as IR, UV–Vis–NIR, elemental analysis,Expand


Butoconazole nitrate 2% for vulvovaginal candidiasis. New, single-dose vaginal cream formulation vs. seven-day treatment with miconazole nitrate. Gynazole 1 Study Group.
This clinical trial demonstrated that butoconazole 1-BSR is an effective and safe alternative to longer-term therapy with miconazole nitrate (seven days) for vulvovaginal candidiasis. Expand
Three-Day Treatment With Butoconazole Nitrate for Vulvovaginal Candidiasis
A multicenter clinical trial of 274 patients compared the efficacy and safety of a new vaginal antifungal compound, butoconazole nitrate cream 2% (butoconazole), to clotrimazole vaginal tablets 200Expand
Single-dose tioconazole compared with 3-day clotrimazole treatment in vulvovaginal candidiasis
Single-dose tioconazole ointment was as effective as a 3-day course of clotrimazole tablets, but significantly more patients in the tioconAZole-treated group experienced local side effects. Expand
Three-day treatment with butoconazole vaginal suppositories for vulvovaginal candidiasis.
Butoconazole is a new imidazole, effective as therapy for vulvovaginal candidiasis for women who prefer solid-type vaginal preparations, and its efficacy was compared to that of clotrimazole vaginal tablets, 200 mg/day. Expand
Single-dose miconazole nitrate vaginal ovule in the treatment of vulvovaginal candidiasis: two single-blind, controlled studies versus miconazole nitrate 100 mg cream for 7 days.
Miconazole nitrate vaginal ovule is as safe and efficacious in curing VVC as Monistat 7 while providing complete symptom relief significantly faster and time to complete relief was significantly faster. Expand
Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.
Long-term weekly treatment with fluconazole can reduce the rate of recurrence of symptomatic vulvovaginal candidiasis, however, a long-term cure remains difficult to achieve. Expand
Vaginal retention of 2% butoconazole nitrate cream: comparison of a standard and a sustained-release preparation.
The purpose of this study was to establish the length of time that butoconazole nitrate 2% standard cream and sustained-release cream could be detected in the vagina after a single administration ofExpand
Tioconazole in the Treatment of Vaginal Candidosis
A 3‐day treatment with tioconazole vaginal tablets (Gyno‐Trosid; Pfizer) was used in 30 patients with vaginal candidosis during a prospective, mycologically controlled study and there was a 100% cure rate on microscopic and mycological examination. Expand
One-day therapy for vaginal candidiasis. A review.
There were few significant differences in either the clinical or mycologic cure rates of single-dose therapy for vaginal candidiasis in nonpregnant women, and no one therapy was consistently better than any other. Expand
Butoconazole vaginal cream in the treatment of vulvovaginal candidiasis. Comparison with miconazole nitrate and placebo.
A double-blind, parallel study was conducted comparing a new imidazole derivative, butoconazole nitrate, with placebo and miconazole nitrate for the treatment of vulvovaginal candidiasis. PatientsExpand